Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)

v3.20.2
Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Disaggregation of Revenue [Line Items]        
Total revenue $ 41,848 $ 24,808 $ 116,429 $ 93,279
Royalties        
Disaggregation of Revenue [Line Items]        
Total revenue 9,005 9,767 22,751 35,931
Kyprolis        
Disaggregation of Revenue [Line Items]        
Total revenue 6,923 7,602 16,809 16,317
Evomela        
Disaggregation of Revenue [Line Items]        
Total revenue 1,802 1,515 4,577 3,570
Other        
Disaggregation of Revenue [Line Items]        
Total revenue 280 650 1,365 1,851
Promacta        
Disaggregation of Revenue [Line Items]        
Total revenue 0 0 0 14,193
Captisol        
Disaggregation of Revenue [Line Items]        
Total revenue 23,389 6,849 68,966 24,357
Contract revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 9,454 8,192 24,712 32,991
Service Revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 7,341 4,548 15,280 12,990
License Fees        
Disaggregation of Revenue [Line Items]        
Total revenue 158 243 1,793 3,083
Milestone        
Disaggregation of Revenue [Line Items]        
Total revenue 960 2,674 4,766 15,425
Other        
Disaggregation of Revenue [Line Items]        
Total revenue $ 995 $ 727 $ 2,873 $ 1,493